Yarrow Bioscience (YARW) Interest & Investment Income (2017 - 2020)
Yarrow Bioscience's (YARW) quarterly Interest & Investment Income came in at $4000.0 in Q3 2020, down 98.95% YoY from $381000.0 in Q4 2019, and down 99.29% on a QoQ basis from $564000.0 in Q2 2020.
Yarrow Bioscience (YARW) Interest & Investment Income (2017 - 2020) Analysis & Trends
Yarrow Bioscience (YARW) has 4 years of Interest & Investment Income data on file, last reported at $4000.0 in Q3 2020.
- Quarterly Interest & Investment Income fell 98.95% year-over-year to $4000.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $31000.0 (down 97.77% YoY) and the FY2019 annual result came in at $120000.0, up 366.67% from the prior year.
- Interest & Investment Income fell to $4000.0 in Q3 2020, from $564000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $728000.0 in Q1 2020 to a low of -$1.3 million in Q4 2019.
- A 4-year average of $88000.0 and a median of $8000.0 in 2017 frame the typical range for Interest & Investment Income.
- The widest YoY moves for Interest & Investment Income: up 783.02% in 2019, down 25400.0% in 2019.
- Tracing YARW's Interest & Investment Income over 4 years: stood at -$36000.0 in 2017, then jumped by 113.89% to $5000.0 in 2018, then slumped by 25400.0% to -$1.3 million in 2019, then surged by 100.32% to $4000.0 in 2020.
- The last three Interest & Investment Income figures came in at $4000.0 (Q3 2020), $564000.0 (Q2 2020), and $728000.0 (Q1 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 4,000.00 |
| Jun 30, 2020 | 564,000.00 |
| Mar 31, 2020 | 728,000.00 |
| Dec 31, 2019 | -1.27 Mn |
| Sep 30, 2019 | 381,000.00 |
| Jun 30, 2019 | 468,000.00 |
| Mar 31, 2019 | 536,000.00 |
| Dec 31, 2018 | 5,000.00 |
| Sep 30, 2018 | 48,000.00 |
| Jun 30, 2018 | 53,000.00 |
| Mar 31, 2018 | -151,000.00 |
| Dec 31, 2017 | -36,000.00 |
| Sep 30, 2017 | -19,000.00 |
| Jun 30, 2017 | 8,000.00 |
| Mar 31, 2017 | -4,000.00 |